Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP19 | O94966 | 7/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20353965 | 0.86 | CA1 (0.38) | USP19CA1L3MBTL1MEN1KMT2A | |
| SCHEMBL16664155 | 0.76 | CA1 (0.50) | CA1L3MBTL1MEN1KMT2AACE2 | |
| SCHEMBL20445091 | 0.75 | L3MBTL1 (0.53) | CA1L3MBTL1MEN1KMT2AACE2 | |
| SCHEMBL27650965 | 0.75 | L3MBTL1 (0.53) | CA1L3MBTL1MEN1KMT2AACE2 | |
| SCHEMBL23049396 | 0.74 | CA1 (0.52) | CA1L3MBTL1MEN1KMT2AACE2 | |
| SCHEMBL23049094 | 0.74 | L3MBTL1 (0.53) | CA1L3MBTL1MEN1KMT2AACE2 | |
| SCHEMBL12351438 | 0.74 | CA1 (0.52) | CA1L3MBTL1MEN1KMT2AACE2 | |
| SCHEMBL12352198 | 0.74 | L3MBTL1 (0.53) | CA1L3MBTL1MEN1KMT2AACE2 | |
| SCHEMBL23482198 | 0.74 | ALDH1A1 (0.41) | USP19CA1L3MBTL1 | |
| SCHEMBL23482193 | 0.74 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2ATDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | USP19 896/4885CA1 4421/4885L3MBTL1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.